Related Experiment Video
Updated: Feb 10, 2026
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
19.8K
Anticancer activity study of A3 adenosine receptor agonists
Gabriella Marucci1, Claudia Santinelli2, Michela Buccioni1
1School of Pharmacy, University of Camerino, via S. Agostino, 1, Camerino, MC 62032, Italy.
Life Sciences
|May 16, 2018
Summary
A novel compound 5 shows significant anticancer effects by inhibiting cancer cell growth and migration. It induces cell death through apoptosis and autophagy, with reactive oxygen species playing a role.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- The A3 adenosine receptor (A3AR) is a potential target for anticancer drug development.
- Identifying selective A3AR agonists is crucial for advancing cancer therapeutics.
Purpose of the Study:
- To evaluate the in vitro anticancer activity of novel synthesized compounds targeting A3AR.
- To investigate the mechanisms of action of potential anticancer agents in various cancer cell lines.
Main Methods:
- Synthesized and screened compounds for A3AR affinity and selectivity.
- Assessed cytotoxicity, growth inhibition, migration, apoptosis, autophagy, and ROS in PC3, Hep G2, and Caco-2 cells.
Main Results:
- Compound 5, at micromolar concentrations, inhibited growth and migration of prostate, liver, and colorectal cancer cells.
- Compound 5 induced apoptosis and autophagy, leading to autophagic cell death.
- Elevated reactive oxygen species (ROS) levels were observed, suggesting their involvement in cell death.
Conclusions:
- Compound 5 demonstrates potent anticancer effects through a multi-mechanistic pathway involving apoptosis and autophagy.
- Compound 5 represents a promising candidate for further development as an anticancer agent.
Keywords:
A(3) adenosine receptorA(3) adenosine receptor ligandsAdenosine derivativesApoptosisAutophagyCancer cellsMigrationReactive oxygen speciesSignal activationMore Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
01:25Drug-Receptor Interaction: Agonist
4.1K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.1K
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
1.0K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.0K
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
523
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
523
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.2K